Disease Overview：Chronic Thromboembolic Pulmonary Hypertension（CTEPH）
Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive, life-threatening form of pulmonary hypertension characterized by unresolved pulmonary artery thrombi that undergo fibrotic remodeling, leading to chronic obstruction, increased pulmonary vascular resistance, right ventricular strain, and eventual heart failure. Unlike acute pulmonary embolism, CTEPH develops when organized thrombi persist for ≥3 months despite adequate anticoagulation, resulting in fixed vascular narrowing and elevated mean pulmonary arterial pressure (≥25 mmHg at rest). Diagnosis requires multimodal evaluation—including high-resolution CT pulmonary angiography, ventilation-perfusion (V/Q) scintigraphy (gold standard for detecting mismatched defects), right heart catheterization, and often digital subtraction pulmonary angiography. While medical therapy (e.g., riociguat) may stabilize some patients, definitive treatment hinges on pulmonary endarterectomy (PEA)—a highly specialized surgical procedure requiring precise dissection of organized thrombus from distal pulmonary arteries—and, for inoperable or residual disease, balloon pulmonary angioplasty (BPA) or targeted pharmacotherapy.
China offers distinct advantages for CTEPH management: leading centers—such as Beijing Anzhen Hospital and Shanghai Pulmonary Hospital—host internationally trained PEA and BPA teams with cumulative experience exceeding 1,000 PEA cases and robust 5-year survival rates (>85%). Advanced intraoperative imaging, real-time hemodynamic monitoring, and hybrid catheter-surgery suites support precision interventions. Treatment costs are typically 40–60% lower than in the US or EU, without compromising clinical standards or accreditation (JCI- and CNAS-certified facilities). As a dedicated medical tourism agency, we facilitate seamless international patient journeys—from initial multidisciplinary case review and hospital coordination to transparent itemized pricing, visa assistance, interpreter services, and post-procedure follow-up—all tailored to optimize outcomes and reduce logistical uncertainty.
Chronic Thromboembolic Pulmonary Hypertension: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Non-Surgical / Medical Management
*Indicated for inoperable patients, post-PEA residual PH, or bridging therapy.*
- •Anticoagulation (Lifelong)
- DOACs (e.g., rivaroxaban 20 mg OD): ¥480–¥650/month ($68–$92)
- •Pulmonary Vasodilators (Targeted Therapy)
- Selexipag (200 µg BID → titrated): ¥4,100–¥4,900/month ($575–$690)
- •Supportive Care & Monitoring
- 6MWT + NT-proBNP + echocardiogram (per visit): ¥1,300–¥1,800 ($180–$250) - CT pulmonary angiography (baseline/follow-up): ¥1,600–¥2,100 ($225–$300)
Surgical / Interventional Options
*Eligibility requires confirmed CTEPH anatomy (distal to main/lobar arteries), mPAP ≥25 mmHg, PVR ≥300 dyn·s·cm⁻⁵, and no contraindications to major surgery.*
- •Pulmonary Endarterectomy (PEA)
- Surgery + ICU stay (7–14 days): ¥185,000–¥240,000 ($26,000–$33,700) - Post-op RHC + rehabilitation (3 months): ¥8,200–¥10,500 ($1,150–$1,475)
- •Balloon Pulmonary Angioplasty (BPA)
- Per-session (1–2 vessels): ¥22,000–¥31,000 ($3,100–$4,350) - Typical course: 3–6 sessions over 6 months → total ¥65,000–¥175,000 ($9,100–$24,600) - Includes pre-BPA RHC, angiography, and post-procedure ICU observation
Special / Complex Condition Management
- •Combined PEA + BPA: For mixed proximal/distal disease — ¥260,000–¥330,000 ($36,500–$46,400)
- •Heart–lung transplant: Reserved for end-stage refractory CTEPH with biventricular failure — ¥680,000–¥820,000 ($95,500–$115,000), including donor matching, surgery, and 1-year immunosuppression
Quick Selection Guide
- •<65 years, low surgical risk, mPAP >45 mmHg: PEA first-line — highest cure potential; cost offset by long-term medication avoidance.
- •≥75 years or severe comorbidities (COPD, renal failure): BPA + riociguat — lower perioperative mortality; avoid upfront surgery.
- •Budget-constrained (<¥100,000/year): Warfarin + supportive care + annual RHC — essential anticoagulation prioritized; delay vasodilators until progression.
- •Post-PEA persistent PH (PVR >500 dyn·s·cm⁻⁵): Riociguat initiation + repeat RHC at 3 months — evidence-supported adjunctive therapy.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Chronic Thromboembolic Pulmonary Hypertension Medical Vacation Packages
Curated transparent all-inclusive packages combining Chronic Thromboembolic Pulmonary Hypertension treatment with China top medical destinations:
